The State of AI/ML in Drug Discovery

This is not another hype piece on AI drug discovery. It’s a clear-eyed commercial read on a sector at the maturity inflection point.

We track the four waves of AI in drug R&D, dissect four viable business models (SaaS, AI-CRO, AI-first biotech, and hybrid) with their actual P&Ls, and map the partnership economics — from $50–100M+ upfronts to billion-dollar milestone structures.

We benchmark validated performance metrics, examine clinical setbacks honestly, and pressure-test what proprietary data moats really look like in 2026. And we name the companies — Insilico, Recursion, Schrödinger, Xaira, Nabla Bio, Isomorphic Labs — with the financials, deal structures, and pipeline data behind every claim.

Built for leaders who need to make portfolio, partnership, and investment decisions before the 2026–2027 Phase 2 readouts reshape the field.

What you’ll walk away knowing

• How leading AI platforms cut preclinical discovery from 2.5–4 years to 12–18 months — and how Insilico’s INS018_055 went concept-to-Phase 1 in under 30 months at <$2.5M.
• Why no AI-discovered drug has been approved yet, and how Phase II/III data through 2026–2027 will separate validated platforms from overpromised ones.
• What 30+ M&A transactions since 2018 — including Recursion–Exscientia — reveal about market consolidation, and how Big Tech (NVIDIA, Alphabet, Microsoft, AWS) is now a direct competitor.
• Why hybrid models are winning commercially — Insilico hit $85.8M revenue at +68% YoY — while pure pipeline plays have lost 80–90% of peak valuations.
• Why data moats now matter more than algorithms, with 3 of pharma’s top 4 adoption barriers being data-related as foundation models commoditize.
• How Genentech, AstraZeneca, Lilly, and Novo Nordisk are scaling internal AI from millions to billions — opening a 5-year gap between leaders and laggards as the pilot era ends.